Virginia Tech researchers report progress in mice with hybrid lipid-polymer nanoparticles that generate antibodies to intercept oxycodone and fentanyl before they cross the blood–brain barrier.
A vaccine using biodegradable nanoparticles coated with opioid molecules produced stronger antibody responses against oxycodone in mice.
Pairing a fentanyl-targeting vaccine with an adjuvant restored its effectiveness in experiments.
Researchers envision use for people with opioid use disorder or individuals at high risk of exposure, as an additional tool alongside existing treatments.
The team created hybrid lipid-polymer nanoparticles that mimic the size and structure of viruses. They coat those particles with opioid molecules such as oxycodone or fentanyl. The immune system then sees the coated particle and produces antibodies targeted to that opioid molecule. Those antibodies bind the drug in the bloodstream, limiting its ability to cross the blood–brain barrier and produce a high.
These vaccines are not designed for broad population-level deployment like seasonal shots. The research team envisions them as targeted interventions for people with opioid use disorder or those at heightened risk of first exposure, including some young people considered vulnerable to trying opioids.
The approach is designed to be highly specific to a single opioid molecule so that it does not interfere with other pain medications a patient might need for medical care. The vaccine delivery system uses biodegradable materials.
The findings appear in the Journal of Controlled Release (reference provided in the study). The work reported here is at the preclinical stage in mice. The research team will need to optimize duration of antibody protection, confirm safety and effectiveness across larger animal models, and then pursue human trials before clinical use could be considered.
If translated to people, a targeted opioid vaccine could be offered to patients in treatment programs, individuals at high occupational risk, or select youth populations to reduce the chance of developing addiction after initial exposures. It could complement overdose-reversal drugs and behavioral or medication-based treatments currently used for opioid use disorder.
The primary study is titled "Innate immune mechanisms underlying the efficacy of a next-generation nanoparticle-based vaccine against opioid use disorders," published in the Journal of Controlled Release (DOI: 10.1016/j.jconrel.2025.114294).
Viagra was initially developed to treat chest pain – could GLP-1s be the next addiction medicine breakthrough?
On the 43-acre campus of EnterHealth Ranch in Van Alstyne, thousands of people have found sobriety through a mix of medication, counseling, functional wellness, nutrition and even brain stimulation therapy. Now, doctors here are adding a new tool to that list: GLP-1 medications, the same class of drugs millions of Amer
Naloxone helped cut overdose deaths 41% from their 2023 peak. But nearly 70,000 still die yearly as survivors cycle through a revolving door without sustained treatment.
When patients with opioid use disorder arrive at the hospital, the admission itself can be a dangerous turning point. Cut off from the unregulated drug supply their bodies have adapted to, they often begin withdrawing within hours, and many choose to leave against medical advice before their illness is ever treated. A
Find out how biotechs are fighting pain with new non-opioid pain medication, as they look to overcome the ongoing opioid crisis. The post New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use
Randox Health The average person spends 20 years of their life in poor health. Let that sink in. But what if you could avoid that? While there are plenty of zeitgeisty ‘ solutions’ to better health floating around in the ether right now, many of them don’t come with a guarantee. It goes without saying that we’d go out
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.